MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Country |
 USA |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
66.4 M |
Market Cap[1] |
$ 2.09 B |
EBITDA (LTM) |
$ -159 M |
P/E (LTM) |
-9.38 |
P/S (LTM) |
290.0 |
EPS (LTM) |
-3.31 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
ADC Therapeutics SA
ADCT
|
$ 3.78 | - | $ 105 M | NYSE |  Schweiz |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Akebia Therapeutics
AKBA
|
$ 1.35 | -2.17 % | $ 347 M | Nasdaq Global Market | USA |
 |
Akari Therapeutics, Plc
AKTX
|
$ 3.5 | -21.7 % | $ 236 B | Nasdaq Capital Market |  Britain |
 |
Aldeyra Therapeutics
ALDX
|
$ 1.58 | -4.82 % | $ 94.9 M | Nasdaq Global Select Market | USA |
 |
Aligos Therapeutics
ALGS
|
$ 8.36 | 4.89 % | $ 82.6 M | Nasdaq Global Select Market | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 330.71 | 3.72 % | $ 43.3 B | Nasdaq Global Select Market,SPB | USA |
 |
Altimmune
ALT
|
$ 3.47 | 3.89 % | $ 306 M | Nasdaq Global Market | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.98 | 0.25 % | $ 106 M | Nasdaq Global Select Market,SPB | USA |
 |
Amgen
AMGN
|
$ 346.45 | -0.43 % | $ 186 B | Nasdaq Global Select Market,SPB | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Amneal Pharmaceuticals
AMRX
|
$ 12.37 | -0.92 % | $ 3.88 B | NYSE | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Anika Therapeutics
ANIK
|
$ 15.0 | 1.32 % | $ 220 M | Nasdaq Global Select Market,SPB | USA |
 |
ANI Pharmaceuticals
ANIP
|
$ 76.34 | 2.87 % | $ 1.47 B | Nasdaq Global Market,SPB | USA |
 |
Annexon
ANNX
|
$ 5.64 | 2.45 % | $ 875 M | Nasdaq Global Select Market | USA |
 |
Aptorum Group Limited
APM
|
$ 0.92 | -1.11 % | $ 5.02 M | Nasdaq Global Select Market | China |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.73 | 2.63 % | $ 4.77 M | Nasdaq Global Select Market,SPB | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.15 | 0.48 % | $ 444 M | Nasdaq Global Market | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 8.43 | 4.98 % | $ 231 M | Nasdaq Global Market,SPB |  Israel |
 |
Ardelyx
ARDX
|
$ 6.08 | 2.27 % | $ 1.47 B | Nasdaq Global Market | USA |
 |
argenx SE
ARGX
|
$ 752.05 | 0.75 % | $ 25 B | Nasdaq Global Select Market |  Niderland |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 23.93 | 1.27 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Arvinas
ARVN
|
$ 11.11 | 2.4 % | $ 788 M | Nasdaq Global Select Market,SPB | USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 61.57 | 0.88 % | $ 8.24 B | Nasdaq Global Select Market,SPB | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Assembly Biosciences
ASMB
|
$ 30.01 | 3.43 % | $ 336 M | Nasdaq Global Select Market,SPB | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.14 | 16.28 % | $ 35.6 M | NYSE American | USA |
 |
Atossa Therapeutics
ATOS
|
$ 5.21 | -2.89 % | $ 44.9 M | Nasdaq Capital Market | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 5.03 | 0.7 % | $ 63.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.04 | 2.75 % | $ 2.16 B | Nasdaq Global Market | Canada |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.42 | 0.35 % | $ 378 M | Nasdaq Global Select Market | Britain |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.